Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, has announced the closing of a $212 million private placement. The company plans to use the net proceeds from this unregistered sale of shares to implement the world's first RAIN prediction markets token digital asset treasury strategy, as well as to continue advancing its core business operations, including the clinical development of AllocetraTM for knee osteoarthritis. The private placement also coincided with the appointment of former Italian Prime Minister Matteo Renzi to the company's Board of Directors. BTIG served as the sole placement agent and exclusive financial advisor for the transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief on November 26, 2025, and is solely responsible for the information contained therein.